Significant R&D payoffs led to massive gains for select pharmaceutical and health-tech companies.
: The Invisalign maker dominated the orthodontic market, reaching record annual sales. It was one of the year's top performers with a 131% return .
Revenues were projected to triple, supporting its in 2017. best stocks to buy right now 2017
: Surged due to rising prices and high demand for memory chips (DRAM and NAND).
Shared value reached approximately market cap, a gain of 87% for the year. Significant R&D payoffs led to massive gains for
: Capitalized on the e-commerce boom and rising digital transaction volumes.
For long-term stability, analysts highlighted established leaders pivoting into new growth markets. Vertex Pharmaceuticals Revenues were projected to triple, supporting its in 2017
: High-volatility winners included Madrigal Pharmaceuticals (+516%) and Sangamo Therapeutics (+438%) due to positive clinical trials and collaboration deals. Blue-Chip Staples and Value Plays